Back to Search
RUZANNA ALEXANIAN, M.D.
M.D.
Internal Medicine Physician
NPI: 1699738047IndividualAccepts Medicare
Specialties, Licenses & Credentials
Internal Medicine PhysicianPrimary
Internal Medicine
Code: 207R00000X
A53476(CA)
CMS Specialties
PrimaryINTERNAL MEDICINE
Education
OTHER
Class of 1985
Research & Publications (20)
Clinical outcomes with intensive therapy for patients with primary resistant multiple myeloma.
PMID 15170166·Bone Marrow Transplant·2004
8-other
Thalidomide with or without dexamethasone for refractory or relapsing multiple myeloma.
PMID 15015890·Semin Hematol·2003
6-review
Consolidation therapy of multiple myeloma with thalidomide-dexamethasone after intensive chemotherapy.
PMID 12176792·Ann Oncol·2002
4-observational
Recent advances in treatment of multiple myeloma and Waldenström's macroglobulinemia.
PMID 11769965·Biomed Pharmacother·2001
6-review
Impact of complete remission with intensive therapy in patients with responsive multiple myeloma.
PMID 11438818·Bone Marrow Transplant·2001
8-other
Randomized trial of alpha-interferon or dexamethasone as maintenance treatment for multiple myeloma.
PMID 11074536·Am J Hematol·2000
3-trial
CR represents an early index of potential long survival in multiple myeloma.
PMID 19633690·Bone Marrow Transplant·2010
8-other
Updated survival analyses after prolonged follow-up of the phase 2, multicenter CREST study of bortezomib in relapsed or refractory multiple myeloma.
PMID 18783399·Br J Haematol·2008
3-trial
Bortezomib in combination with thalidomide-dexamethasone for previously untreated multiple myeloma.
PMID 17558699·Hematology·2007
3-trial
Results of a retrospective single institution analysis of targeted skeletal radiotherapy with (166)Holmium-DOTMP as conditioning regimen for autologous stem cell transplant for patients with multiple myeloma. Impact on transplant outcomes.
PMID 17448913·Biol Blood Marrow Transplant·2007
8-other
Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib.
PMID 16754936·J Clin Oncol·2006
3-trial
Safety of prolonged therapy with bortezomib in relapsed or refractory multiple myeloma.
PMID 16206291·Cancer·2005
3-trial
Prognostic significance of magnetic resonance imaging of bone marrow in previously untreated patients with multiple myeloma.
PMID 16087694·Ann Oncol·2005
8-other
Thalidomide-dexamethasone as primary therapy for advanced multiple myeloma.
PMID 15981221·Am J Hematol·2005
3-trial
Atiprimod blocks STAT3 phosphorylation and induces apoptosis in multiple myeloma cells.
PMID 15970928·Br J Cancer·2005
8-other
Bortezomib in recurrent and/or refractory multiple myeloma. Initial clinical experience in patients with impared renal function.
PMID 15690325·Cancer·2005
4-observational
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 1560 E CHEVY CHASE DR STE 245
GLENDALE, CA 91206 - Phone
- (818) 246-5900
Quick Facts
- NPI
- 1699738047
- Entity Type
- Individual
- Gender
- Female
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 1
- Years in Practice
- 41
- Publications
- 20
Are you this provider?
Claim Your Profile